Can Ixazomib/Enleri cure myeloma? Can it be cured?

Ixazomib/Ixazomib is an oral proteasome inhibitor mainly used for the treatment of multiple myeloma. Although it has shown good efficacy in clinical applications, it needs to be clear that there is currently no drug that can completely cure multiple myeloma. Ixazomib is often used as part of a treatment regimen to control the disease and slow its progression.

Multiple myeloma (MM) is a clonal disease of plasma cells characterized by the accumulation of clonal plasma cells in the bone marrow (and other organs), bone lesions, anemia and, less commonly, hypercalcemia. Other more common complications are infection, pain, renal impairment, and neurological symptoms. Multiple myeloma accounts for approximately 1% of all reported tumors and approximately 13% of hematologic cancers worldwide.

Currently, it takes 5-6 years from diagnosis of multiple myeloma to diagnosis Although the treatments for this disease have been continuously updated in recent years, and targeted drugs like ixazomib have significantly improved the survival rate and quality of life of patients, they are still essentially a means of managing the disease. The mechanism of action of ixazomib is by inhibiting proteasome activity in cells, leading to the accumulation of unnecessary or harmful proteins in cancer cells, and ultimately inducing cancer cell death. This mechanism allows it to exhibit synergistic effects when used in combination with other drugs. For example, ixazomib is often combined with immunomodulators (such as lenalidomide) and corticosteroids (such asdexamethasone) to enhance the therapeutic effect.

A previously phase III randomized, double-blind, placebo-controlled, multicenter study confirmed the efficacy of ixazomib. Patients with relapsed and/or refractory MM (n = 722) were randomized to receive ixazomib, lenalidomide, and dexamethasone (n = 362) or placebo, lenalidomide, and dexamethasone (n = 360). Ixazomib had a statistically significant (p=0.012) progression-free survival (PFS) advantage, with a median PFS of 20.6 months compared with 14.7 months in the control group.

During treatment, patient responses vary from individual to individual. Some patients may experience longer remissions, while others may face recurrence of the disease. In clinical trials, ixazomib has shown promising efficacy, particularly in patients with relapsed/refractory multiple myeloma who have been treated with other therapies. However, this does not equal a cure.

Although the side effects of ixazomib are relatively mild and commonly include diarrhea, constipation, nausea, vomiting, fluid retention, peripheral neuropathy, back pain, thrombocytopenia, and rash, possible serious side effects such as thrombocytopenia and increased risk of infection still need to be monitored. Therefore, patients should undergo regular blood tests and related monitoring while receiving treatment to ensure that possible complications are detected and dealt with in a timely manner.

Although ixazomib plays an important role in the treatment of multiple myeloma, treatment regimens often need to be individualized. When choosing a specific treatment plan, doctors will consider factors such as the patient's overall health, disease progression, and response to past treatments.